| Natallia Breibart, DO | |
|
1505 W Sherman Ave, Vineland, NJ 08360-7059 | |
| (856) 641-8000 | |
| Not Available |
| Full Name | Natallia Breibart |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 8 Years |
| Location | 1505 W Sherman Ave, Vineland, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487009114 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 25MB10483300 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Inspira Medical Center Vineland | Vineland, NJ | Hospital |
| Inspira Medical Center Elmer | Elmer, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cooper Physician Offices Pa | 2860396611 | 241 |
News Archive
Labcyte, the developer of acoustic liquid transfer, with systems in all top 10 pharmaceutical companies, today announced the selection of Bioscreen Instruments Pvt. Ltd. as its exclusive distributor in India.
As scientific research delves into the processes underlying human disease, doctors are challenged to integrate these new discoveries into patient care. To help bridge the gap between basic science research and clinical practice, a new series on "Pathophysiology in Medicine" begins this month in The American Journal of the Medical Sciences (The AJMS), official journal of the Southern Society for Clinical Investigation.
For the study the team studied samples of lung tumors and nearby healthy lung tissue from 30 patients and examined the samples for the presence of messenger ribonucleic acid (mRNA) associated with 48 known genes for molecules called nuclear hormone receptors. Then they compared the active genes with patient outcomes and found that the expression of genes for certain nuclear hormone receptors helped predict patient survival.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has initiated an open-label Phase 1b safety and dose escalation clinical trial with INNO-206 at the Sarcoma Oncology Center in Santa Monica, California. The clinical trial will include up to 24 patients with advanced solid tumors who have failed standard therapies.
With the growing prevalence of chronic pain, depression, anxiety, and other symptom-based conditions, physicians and the healthcare systems for which they work are increasingly considering how to augment the care they can provide within the limited time allotted for patient appointments.
› Verified 6 days ago
| Entity Name | Cooper Physician Offices Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154369510 PECOS PAC ID: 2860396611 Enrollment ID: O20031122000067 |
News Archive
Labcyte, the developer of acoustic liquid transfer, with systems in all top 10 pharmaceutical companies, today announced the selection of Bioscreen Instruments Pvt. Ltd. as its exclusive distributor in India.
As scientific research delves into the processes underlying human disease, doctors are challenged to integrate these new discoveries into patient care. To help bridge the gap between basic science research and clinical practice, a new series on "Pathophysiology in Medicine" begins this month in The American Journal of the Medical Sciences (The AJMS), official journal of the Southern Society for Clinical Investigation.
For the study the team studied samples of lung tumors and nearby healthy lung tissue from 30 patients and examined the samples for the presence of messenger ribonucleic acid (mRNA) associated with 48 known genes for molecules called nuclear hormone receptors. Then they compared the active genes with patient outcomes and found that the expression of genes for certain nuclear hormone receptors helped predict patient survival.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has initiated an open-label Phase 1b safety and dose escalation clinical trial with INNO-206 at the Sarcoma Oncology Center in Santa Monica, California. The clinical trial will include up to 24 patients with advanced solid tumors who have failed standard therapies.
With the growing prevalence of chronic pain, depression, anxiety, and other symptom-based conditions, physicians and the healthcare systems for which they work are increasingly considering how to augment the care they can provide within the limited time allotted for patient appointments.
› Verified 6 days ago
| Entity Name | Community Health Care, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700816816 PECOS PAC ID: 9335040419 Enrollment ID: O20040402000981 |
News Archive
Labcyte, the developer of acoustic liquid transfer, with systems in all top 10 pharmaceutical companies, today announced the selection of Bioscreen Instruments Pvt. Ltd. as its exclusive distributor in India.
As scientific research delves into the processes underlying human disease, doctors are challenged to integrate these new discoveries into patient care. To help bridge the gap between basic science research and clinical practice, a new series on "Pathophysiology in Medicine" begins this month in The American Journal of the Medical Sciences (The AJMS), official journal of the Southern Society for Clinical Investigation.
For the study the team studied samples of lung tumors and nearby healthy lung tissue from 30 patients and examined the samples for the presence of messenger ribonucleic acid (mRNA) associated with 48 known genes for molecules called nuclear hormone receptors. Then they compared the active genes with patient outcomes and found that the expression of genes for certain nuclear hormone receptors helped predict patient survival.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has initiated an open-label Phase 1b safety and dose escalation clinical trial with INNO-206 at the Sarcoma Oncology Center in Santa Monica, California. The clinical trial will include up to 24 patients with advanced solid tumors who have failed standard therapies.
With the growing prevalence of chronic pain, depression, anxiety, and other symptom-based conditions, physicians and the healthcare systems for which they work are increasingly considering how to augment the care they can provide within the limited time allotted for patient appointments.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Natallia Breibart, DO 1 Federal St Sw 200, Camden, NJ 08103 Ph: (856) 356-4924 | Natallia Breibart, DO 1505 W Sherman Ave, Vineland, NJ 08360-7059 Ph: (856) 641-8000 |
News Archive
Labcyte, the developer of acoustic liquid transfer, with systems in all top 10 pharmaceutical companies, today announced the selection of Bioscreen Instruments Pvt. Ltd. as its exclusive distributor in India.
As scientific research delves into the processes underlying human disease, doctors are challenged to integrate these new discoveries into patient care. To help bridge the gap between basic science research and clinical practice, a new series on "Pathophysiology in Medicine" begins this month in The American Journal of the Medical Sciences (The AJMS), official journal of the Southern Society for Clinical Investigation.
For the study the team studied samples of lung tumors and nearby healthy lung tissue from 30 patients and examined the samples for the presence of messenger ribonucleic acid (mRNA) associated with 48 known genes for molecules called nuclear hormone receptors. Then they compared the active genes with patient outcomes and found that the expression of genes for certain nuclear hormone receptors helped predict patient survival.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has initiated an open-label Phase 1b safety and dose escalation clinical trial with INNO-206 at the Sarcoma Oncology Center in Santa Monica, California. The clinical trial will include up to 24 patients with advanced solid tumors who have failed standard therapies.
With the growing prevalence of chronic pain, depression, anxiety, and other symptom-based conditions, physicians and the healthcare systems for which they work are increasingly considering how to augment the care they can provide within the limited time allotted for patient appointments.
› Verified 6 days ago
Shannon Hope Harrington, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1505 W Sherman Ave, Vineland, NJ 08360 Phone: 856-641-8000 | |
Hima Bodagala, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 1505 W Sherman Ave, Vineland, NJ 08360 Phone: 856-845-0100 Fax: 302-651-4945 | |
Dr. Kanika Gupta, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1505 W Sherman Ave, Vineland, NJ 08360 Phone: 856-845-1000 |